Insmed Incorporated (INSM) earnings on October 29, 2026

Before the market opens Q3 2026

More Insmed Incorporated earnings

Prior outlook: Optimistic Outcome: Accurate

INSM soared 21.76% intraday after strong results and closed 15.06% higher, joining a broad rise in smaller healthcare stocks.

INSM price around the earnings

111.59

Change: +15.1%

2026-10-29, 20:00 UTC

Start of the measured window End of the measured window
95.74 102.64 109.55 116.45 96.98
Price series around the eventClosing price per minute from before the event to the end of the measured window.
October 29, 2026
  • Price: green if it ends above the starting price; red if it ends below
  • Start of the measured window
  • End of the measured window
  • Market open
  • Starting price
Price series around the event

Prior thesis

Prior outlook: Optimistic Outcome: Accurate

Thesis published
Results released

The scenario for the price is optimistic and outweighs cautious news and crowd sentiment. Analysts cite strong price targets alongside modest growth expectations, although recent price weakness and mixed earnings reactions keep the outlook from looking one-sided.

Context analyzed before publication

Playbook
Recent underperformance contrasts with strong analyst targets and favorable past earnings. Price volatility tends to be high, and recent price moves have been substantial.
Trend
Analyst optimism peaked, then softened

Analysts

Drivers

  • Analysts Positive

    Across 22 analyst opinions, a strongly positive rating points to a $196 target, 102.2% above the reference price.

Evidence

Analyst consensus
Strong buy
Consensus average (1-5)
1.29
Analysts covering the stock
22
Average price target
196.14
Lowest price target
165
Highest price target
243
Upside to price target
102.2%
Revenue growth
296.1%
Forward EPS
0.79
Trailing EPS
-4.1
Analyst moves in the last 60 days
5
  • Strong buy: 5
  • Buy: 18
  • Hold: 1
  • Sell: 0
  • Strong sell: 0
Strong buy
5
Buy
18
Hold
1
Sell
0
Strong sell
0
  • October 21, 2026 · Morgan Stanley: Maintains rating (Overweight → Overweight)
  • October 12, 2026 · Wolfe Research: Downgrades rating (Outperform → Peer Perform)
  • October 12, 2026 · HC Wainwright & Co.: Reiterates rating (Buy → Buy)
  • September 30, 2026 · Barclays: Maintains rating (Overweight → Overweight)
  • September 15, 2026 · Roth Capital: Reiterates rating (Buy → Buy)

News and sentiment

Drivers

  • News & sentiment Negative

    Morgan Stanley maintained a positive rating but reduced its target to $213, while public sentiment remains fully optimistic.

Evidence

Sentiment
Sentiment
Constructive
Mention volume
High
Normalized volume
99%
Messages
30

Technicals

Drivers

  • Technical Negative

    The 30-day return was -17.44%, while SPY gained 0.89%. Performance relative to the broader market was also weak, but the scenario points optimistic.

Evidence

Price when the context was analyzed
97.17
Average true range (ATR)
3.2%
Distance to 52-week high
-54.1%
14-day change (14d)
-0.7%
30-day change (30d)
-17.4%
30-day relative strength
-18.3%
SPY change (30d)
+0.9%
Nearest support
96.53
Distance to nearest support
0.7%
Nearest resistance
97.21
Distance to nearest resistance
0%
Volume accumulation ratio (14d / 46d)
1.24
  • Mid: 96.53 (0.7% away, 0.2 ATR, 16 touches)
  • Minor: 95.4 (1.8% away, 0.57 ATR, 8 touches)
  • Minor: 93.95 (3.3% away, 1.03 ATR, 9 touches)
  • Mid: 97.21 (0% away, 0.01 ATR, 13 touches)
  • Mid: 97.87 (0.7% away, 0.23 ATR, 15 touches)
  • Mid: 99.02 (1.9% away, 0.6 ATR, 16 touches)

Trends

Evidence

Average earnings surprise
+13.9%
  • August 6, 2026: actual EPS -0.06 vs estimate -0.68 (surprise +91.2%)
  • May 7, 2026: actual EPS -0.76 vs estimate -1 (surprise +23.9%)
  • February 19, 2026: actual EPS -1.54 vs estimate -1.17 (surprise -31.9%)
  • October 30, 2025: actual EPS -1.75 vs estimate -1.37 (surprise -27.8%)

Expected move

Drivers

  • Past earnings Positive

    August earnings per share beat estimates by 91.2%. The price then jumped 30.0% and continued another 34.2%.

Implied move
+4.5%
Source
Options chain

Reactions over its last 21 earnings

Median move
2.4%
75th percentile move
6.3%
90th percentile move
16.6%
Up / down moves
11 / 10
Average up move
+8.3%
Average down move
-4.8%

Monitoring and close

What Insmed Incorporated reported

Status
Finished
Actual EPS-0.46
EPS estimate-0.43
EPS surprise-7.0%
Revenue$524 million
Revenue estimate$501 million
Revenue surprise+4.6%

Insmed appeared among premarket gainers after strong earnings and raised guidance, while Alphabet fell 11.8% and small-cap stocks rallied as GDP growth beat expectations.

Sources (7)

Pre-market second reading after the results

Verdict
Missed expectations

Heading into the open, Results beat expectations on revenue but not on earnings and the price is indicating +13.4% pre-market, a move 6x the stock's usual reaction (about 2%). The figures confirm the optimistic scenario. Across our market history, in the 461 similar cases the close held that direction 94% of the time.

How the stock reacted

Outcome
Accurate
Consolidated
+15.1%
Max favorable move (MFE)
21.8%
Max adverse move (MAE)
1.3%